Precision medicine uses some of the world’s most sophisticated technologies to find the root causes of each patient’s unique condition and apply the best, most precise treatments. California is a biomedical juggernaut, and the precision medicine research being funded today will impact patients around the world. Learn how California is leading the way in precision medicine research.
CLSA President & CEO Mike Guerra pens an op-ed in Morning Consult regarding the dangers of policymakers utilizing foreign price controls to lower drug costs. With growing bipartisan support for these schemes, CLSA is working to educate policymakers that importing price controls will do little to lessen the financial burden for patients. Rather, these short-sighted proposals will hinder access to needed treatments and discourage medical innovation in California.
“We all agree that drug prices are high, but a proposal before the Legislature would make that situation worse, even as it seeks to solve the problem.” Read more about AB 824 in CalMatters.
CLSA Board Member Wendye Robbins, MD, President & CEO of Blade Therapeutics, pens an op-ed in the San Francisco Chronicle, urging the Legislature to make key changes to Assembly Bill 824, priority legislation for CLSA that seeks to prohibit generic drug manufacturers from seeking patent settlement agreements.
New medicines, devices, and diagnostics produced by the life sciences community in California are giving clinicians better tools to fight disease and improve quality of life for patients around the world. CLSA President & CEO Mike Guerra pens an op-ed in Xconomy on the strength and growth of California’s life sciences sector.
Assemblyman Rob Bonta, Co-Chair of the California Legislative Rare Disease Caucus, pens an op-ed in The Sacramento Bee on the need to raise awareness and help California develop strong public policies to streamline the drug development pipeline and ensure that everyone with a rare disease gets the treatment they deserve.
Assembly Bill 375, the California Consumer Privacy Act, will require companies that store large amounts of data, such as Google, Facebook, Twitter, and others, to disclose what kinds of data they collect, and give consumers more control over how that data is shared.
CLSA Board Member David Beier pens an op-ed in STAT News regarding the impact of the 2.3% medical device tax on patient care and innovation.
CLSA President & CEO Sara Radcliffe pens an op-ed in the San Diego Business Journal regarding the need to nurture California and San Diego’s innovative life sciences industry.
Sara Radcliffe, Pres. & CEO, CLSA & Don Bobo, Corporate Vice President, Strategy & Corporate Development, Edwards Lifesciences, pen an op-ed in The O.C. Register, urging Congress repeal the 2.3% medical device tax. The tax stands to threaten an innovative medtech sector that employs over 22,000 in Orange County and 77,200 statewide.